ECE2017 Eposter Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (145 abstracts)
Hypertension, acromegaly and pegvisomant treatment: Experience from ACROSTUDY
Greisa Vila 1 , Arrt Jan vanderLely 2 , Sebastian Neggers 2 , Anton Luger 1 , Susan Webb 3 , Beverly Biller 4 , Peter Jonsson 5 & Judith Hey-Hadavi 6
1Medical University of Vienna, Vienna, Austria; 2Erasmus University Medical Centre, Rotterdam, The Netherlands; 3Universitat Autonoma de Barcelona, Barcelona, Spain; 4Massachusetts General Hospital, Boston, Massachusetts, USA; 5Pfizer ACROSTUDY Endocrine Care, Sollentuna, Sweden; 6Pfizer Endocrine Care, New York, USA.
Introduction: Hypertension (HTN) is a major cardiovascular (CV) risk factor and independent predictor of the increased mortality in patients with acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure (BP) levels, however little is known on the effect of pegvisomant (PEGV) treatment on HTN.
Methods/design: ACROSTUDY is an open-label, international, prospective, non-interventional study monitoring the long-term safety of PEGV. After informed consent, study patients were enrolled on an ongoing basis. Data were analysed to identify the clinical characteristics and evolution of HTN in patients with acromegaly treated with PEGV.
Results: As of May 31, 2016, data from 2090 patients (15 countries) were available. At ACROSTUDY start, 1038 patients (49.7%, 51% male) had diagnosed HTN (96.4% were on anti-HTN medications). Most HTN patients were Caucasian (95%) and 75.8% was treated with PEGV before ACROSTUDY start. Modifiable CV risk factors that were reported besides HTN were BMI >25 (87.2%), diabetes (72.2%), dyslipidemia (10.2%), sleep apnoea (71.8%), and 17.7% had history of CVD. In the HTN group, the mean age at diagnosis of acromegaly was 48 years (S.D. 12.7) and the mean age at the start of PEGV (Baseline) was 56 years (S.D. 12.1) vs 36.3 years (S.D.11.7) and 43 years (S.D. 12.7) for non-HTN group. Time from diagnosis to PEGV treatment was 8.4 years (S.D. 8.5) vs 6.5(S.D. 7.2) in HTN and non-HTN group respectively. At baseline systolic BP(SBP) was 138.3 and diastolic BP(DBP) 85 mmHg. Follow up at year 5 showed SBP 134.5 and DBP 82.5 mmHg. Average IGF-1 level at baseline was 488.9 and 218 ng/ml at year 5.
Conclusions: HTN is a common comorbidity in acromegaly. Patients with HTN tend to be older at diagnosis and start of PEGV and have multiple CV risk factors. With PEGV treatment, blood pressure levels remain stable over time.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more